JP2024537284A - 抗ｎｐｒ１抗体を投与することにより血行動態の変化を引き起こす方法 - Google Patents

抗ｎｐｒ１抗体を投与することにより血行動態の変化を引き起こす方法 Download PDF

Info

Publication number
JP2024537284A
JP2024537284A JP2024521784A JP2024521784A JP2024537284A JP 2024537284 A JP2024537284 A JP 2024537284A JP 2024521784 A JP2024521784 A JP 2024521784A JP 2024521784 A JP2024521784 A JP 2024521784A JP 2024537284 A JP2024537284 A JP 2024537284A
Authority
JP
Japan
Prior art keywords
antibody
dose
subject
antigen
npr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024521784A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024537284A5 (https=
JPWO2023064769A5 (https=
Inventor
マイケル・ダン
アーロン・キッスカート
ベンジャミン・アダム・オーレンショック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2024537284A publication Critical patent/JP2024537284A/ja
Publication of JP2024537284A5 publication Critical patent/JP2024537284A5/ja
Publication of JPWO2023064769A5 publication Critical patent/JPWO2023064769A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024521784A 2021-10-11 2022-10-11 抗ｎｐｒ１抗体を投与することにより血行動態の変化を引き起こす方法 Pending JP2024537284A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163254447P 2021-10-11 2021-10-11
US63/254,447 2021-10-11
PCT/US2022/077908 WO2023064769A1 (en) 2021-10-11 2022-10-11 Methods of effecting a hemodynamic change by administering an anti-npr1 antibody

Publications (3)

Publication Number Publication Date
JP2024537284A true JP2024537284A (ja) 2024-10-10
JP2024537284A5 JP2024537284A5 (https=) 2025-12-22
JPWO2023064769A5 JPWO2023064769A5 (https=) 2025-12-22

Family

ID=84045029

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024521784A Pending JP2024537284A (ja) 2021-10-11 2022-10-11 抗ｎｐｒ１抗体を投与することにより血行動態の変化を引き起こす方法

Country Status (12)

Country Link
US (2) US20240327539A1 (https=)
EP (1) EP4415820A1 (https=)
JP (1) JP2024537284A (https=)
KR (1) KR20240099275A (https=)
CN (1) CN118159290A (https=)
AU (1) AU2022363841A1 (https=)
CA (1) CA3234238A1 (https=)
CL (1) CL2024001071A1 (https=)
CO (1) CO2024005662A2 (https=)
IL (1) IL311917A (https=)
MX (1) MX2024004302A (https=)
WO (1) WO2023064769A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL313265A (en) 2021-12-06 2024-08-01 Regeneron Pharma Antagonistic antibodies against NPR1 and methods of using them
WO2024251255A1 (zh) * 2023-06-08 2024-12-12 江苏恒瑞医药股份有限公司 抗npr1抗体及其医药用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US9090695B2 (en) 2008-12-03 2015-07-28 Morphosys Ag Antibodies for guanylyl cyclase receptors
MY205168A (en) 2018-10-23 2024-10-04 Regeneron Pharma Anti-npr1 antibodies and uses thereof
EA202193345A1 (ru) * 2019-06-12 2022-03-16 Новартис Аг Антитела к рецептору-1 натрийуретического пептида и способы их применения
US12325752B2 (en) * 2020-12-18 2025-06-10 Regeneron Pharmaceuticals, Inc. Immunoglobulin proteins that bind to NPR1 agonists

Also Published As

Publication number Publication date
WO2023064769A1 (en) 2023-04-20
AU2022363841A1 (en) 2024-03-28
US20240327539A1 (en) 2024-10-03
IL311917A (en) 2024-06-01
MX2024004302A (es) 2024-06-19
CL2024001071A1 (es) 2024-12-06
KR20240099275A (ko) 2024-06-28
CA3234238A1 (en) 2023-04-20
CO2024005662A2 (es) 2024-05-10
US20250034279A1 (en) 2025-01-30
EP4415820A1 (en) 2024-08-21
CN118159290A (zh) 2024-06-07

Similar Documents

Publication Publication Date Title
US20240390489A1 (en) Methods of increasing strength and functionality with gdf8 inhibitors
US12377144B2 (en) Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
US20250034279A1 (en) Methods of effecting a hemodynamic change by administering an anti-npr1 antibody
ES3037632T3 (en) A leptin receptor agonist antibody for use in increasing bone mass in a subject suffering from metabolic dysfunction or hypoleptinemia
US20250145700A1 (en) Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)
JP2022538237A (ja) Ｂ細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療
RS66543B1 (sr) Strategija doziranja koja ublažava sindrom oslobađanja citokina za cd3/cd20 bispecifična antitela
US20240425574A1 (en) Anti-pdgf-b antibodies and pharmaceutical composition thereof
JP2025533075A (ja) 二重特異性ＥＧＦＲｘＣＤ２８抗体単独又は抗ＰＤ－１抗体との併用による癌治療方法
US20160244520A1 (en) Compositions and methods for treating psoriatic arthritis
WO2025166169A1 (en) Compositions, doses, and methods for treatment of c1s mediated diseases and disorders
HK40097452A (en) Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)
KR20250011951A (ko) 인터루킨-17 (il-17) 길항제를 사용한 거대 세포 동맥염의 치료 방법
WO2021207667A1 (en) Compositions and methods for treating lung injury or acute respiratory distress syndrome (ards)
EA049619B1 (ru) Способы лечения аллергии с применением антител к bet v 1
HK40055105B (en) Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)
HK40055105A (en) Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251212